Close menu




Biotechnology

Photo credits: pixabay.com

Commented by Stefan Feulner on April 29th, 2022 | 11:16 CEST

BioNTech, NervGen, Sanofi - The rebound is on the way

  • Biotechnology
  • Healthcare

Uncertainties remain. Admittedly, infection figures are falling in the Corona pandemic and should ensure a quiet summer in this respect. In addition to inflation remaining at a high level, the Ukraine conflict moved to the front news pages. It has caused panic and strong sales on the stock markets in recent weeks. After the DAX marked another interim low at around 13,500 points yesterday, the stock market barometer turned around but is struggling with the psychologically important mark at 14,000 points. Now the quarterly season has begun, which could provide positive impetus. Commerzbank and Deutsche Bank started it off and were quite convincing.

Read

Commented by Fabian Lorenz on April 28th, 2022 | 13:00 CEST

BioNTech share price about to double? Varta and Meta Materials with newsflow, or not

  • Biotechnology
  • Technology

Those who are currently betting on rising prices on the stock market need strong nerves. But some companies are worth a closer look. Among others, this applies to BioNTech. The Company is facing important deadlines, continues to earn billions with its Corona vaccine and has an attractive product pipeline. The analysts at Berenberg, for example, see doubling potential after the stock has bottomed out. Meta Materials has also formed a bottom formation, and at the same time, there was positive newsflow from the developer of revolutionary products. Varta shareholders have been hoping for this for some time, but in vain. The share is battered, and even the current financial injection cannot change that.

Read

Commented by Nico Popp on April 27th, 2022 | 11:54 CEST

Where the sentiment is right: BioNTech, Defence Therapeutics, Amazon

  • Biotechnology

If you want to sell air mattresses in November, you will not succeed even with huge discounts. It is a similar story when selecting stocks. In order to reap returns, investors need to assess the market and bet on the stocks that will be in demand in the near future. In the case of vaccine stocks, the air seemed to be out recently. But now, there are growing indications that more vaccine doses may be needed. We take a look at the sentiment of three stocks.

Read

Commented by Nico Popp on April 20th, 2022 | 10:29 CEST

The million-dollar opportunity: Valneva, Edgemont Gold, BASF

  • Gold
  • Copper
  • Biotechnology

No one can see into the future. But investors can estimate which topics will move share prices in the near future. There is not always a connection between what is important and what is played out in the media. Issues such as climate change are timeless but disappear from the front pages from time to time. It is currently a similar situation with the pandemic. We dare to take a look into the future and ask what could move prices this summer.

Read

Commented by Stefan Feulner on April 19th, 2022 | 12:10 CEST

Bayer, Defence Therapeutics, Formycon - Biotech stocks facing transformation

  • Biotechnology

The pharmaceutical industry proved to be a key industry in the Corona pandemic, developing tests, vaccines and drugs at record speed and making them available in large quantities. In the process, biotechnology emerged as the innovative engine. The development of new compounds is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs will expire in the future or has already expired. For this reason, the pharmaceutical industry is now entering biotechs much more frequently in the early development phases of a new drug. As a result, early-stage development companies already offer opportunities for multiplication.

Read

Commented by André Will-Laudien on April 19th, 2022 | 10:49 CEST

Watch out: BioNTech, NervGen, Valneva, CureVac: The next waves of biotech stocks are rolling!

  • Biotechnology

The start of spring - and where to now? The mild flu outbreaks due to the Omicron variant and associated massive relaxations of Corona measures in many countries are weighing on the prospects of vaccine manufacturers in the short term. After all, there are no clinical bottlenecks, and the vaccination rate does not want to increase despite massive public campaigns. Mandatory vaccination is also off the table, and for the biotech industry and vaccine producers, this results in a need to keep researching other topics! Many diseases are more dangerous for us humans than Corona. We look at important protagonists.

Read

Commented by André Will-Laudien on April 6th, 2022 | 10:46 CEST

Siemens Healthineers, Perimeter Medical, Siemens, SAP - After BioNTech, now the push for MedTech shares!

  • medtech
  • Biotechnology
  • Software

The most significant positive share price developments in the last 12 months occurred in the biotech sector, especially among vaccine manufacturers such as BioNTech and Moderna. The stock market overlooked that pandemics, and the fight against them, offer short-term profit opportunities. The great battle against widespread diseases such as cardiovascular disease, cancer or other previously incurable indications progresses steadily. Their diagnosis and treatment require many types of technology, devices, processes, analysis tools, and intelligent software. Some methods certainly deserve the attribute "disruptive technology". We take a look at some blockbusters in the MedTech segment.

Read

Commented by André Will-Laudien on April 4th, 2022 | 12:19 CEST

Bayer, Cardiol Therapeutics, Formycon, NanoRepro: Top Biotech Stocks - Delivering!

  • Biotechnology

Due to various public easing measures, the Corona pandemic is increasingly fading into the background. It has long been a hot ride for the stock market, especially for vaccine producers, but now investors are shifting their focus to other stocks in the biotech segment. After all, there are still many diseases that confront humanity with unresolved mysteries, and the field of human medical research seems endless. We focus on interesting stocks from the sector, which corrected strongly in the wake of the Ukraine downturn but are now trending north again. These trends are still in their infancy.

Read

Commented by Nico Popp on April 4th, 2022 | 11:20 CEST

Millions with innovations: BioNTech, Meta Materials, Varta

  • Technology
  • Biotechnology

When the long-forgotten solar company SolarWorld went public in 1999, n-tv ran commercials that, from today's perspective, looked rather amateurish. At that time, too, only a few private investors were initially convinced by the Company. Years later, SolarWorld was a success story - investors from the very beginning had become rich. Even though the Company filed for insolvency in the meantime and burned a lot of money - SolarWorld investors of the first hour are mostly still wealthy. We explain where innovations can develop blockbuster potential.

Read

Commented by André Will-Laudien on April 1st, 2022 | 12:43 CEST

BioNTech, Defence Therapeutics, Valneva, CureVac - Stocks with blockbuster potential!

  • Biotechnology

With the Ukraine crisis, international vaccination activity has taken a back seat. The world's northern hemisphere is gearing up for next summer, so flu diseases are also slowly taking a back seat. However, the COVID virus will likely continue to mutate over the summer and will reappear in a new guise in the fall. Germany's maximum vaccination rate of 76% has been reached, with just under a quarter of the population ultimately foregoing vaccination after lengthy public measures. For the major biotech companies, it is now a case of - The country needs new products! There are still many areas of application in the field of mRNA. Which stocks stand out with their pipeline?

Read